Posts Tagged: Novartis
Federal Circuit Upholds Patent Term Extension for Novartis Drug
The United States Court of Appeals for the Federal Circuit recently affirmed a district court decision finding the '229 patent valid, unexpired, enforceable, and infringed, and granting …
Novartis acquires French radiopharmaceutical firm for oncology drug after losing patent protection for Gleevec
Novartis has agreed to acquire French radiopharmaceutical firm Advanced Accelerator Applications (AAA) in a deal which values AAA at $3.9 billion USD. The deal, funded through short- and …
FDA approval of Teflaro puts Allergan’s portfolio of anti-infectives into focus
Treatments for infectious diseases is one area where Allergan is looking to buoy its fortunes in the coming years. The first quarter of 2016 was a strong one …
Bristol-Myers Squibb, Exelixis drugs to aid in fight against kidney cancer
Bristol-Myers Squibb was able to move on in clinical trials of its cancer drug Opvido more quickly than anticipated after kidney cancer patients who were administered the …
Deadline Approaches for Public Comments on Patent Term Adjustment
Novartis filed law suits that challenged the determinations by the USPTO of how much time to add to the patent term under 35 U.S.C. § 154(b) with …
Global IP Reaction to India’s Rejection of the Novartis Drug Patent
India’s booming $26 billion generic drug industry and public health sector rejoiced over the Indian Supreme Court’s recent decision to reject a patent filed by the …
